Evidence map›Paper›PMID 41982683›Full record

ArticleTranslational lung cancer research2026

Proposal on incorporating consolidation-to-tumor ratio into the clinical T1 classification in patients with invasive lung adenocarcinoma.

Molin Zhang, Chaoqiang Deng, Fangqiu Fu, Ting Ye, Akif Turna, Yuan Li, Yang Zhang, Haiquan Chen

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Translational lung cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Molin Zhang *Department of Thoracic Surgery and State Key Laboratory of Genetics and Development of Complex Phenotypes, Fudan University Shanghai Cancer Center, Shanghai, China.
Chaoqiang Deng *Department of Thoracic Surgery and State Key Laboratory of Genetics and Development of Complex Phenotypes, Fudan University Shanghai Cancer Center, Shanghai, China.
Fangqiu FuDepartment of Thoracic Surgery and State Key Laboratory of Genetics and Development of Complex Phenotypes, Fudan University Shanghai Cancer Center, Shanghai, China.
Ting YeDepartment of Thoracic Surgery and State Key Laboratory of Genetics and Development of Complex Phenotypes, Fudan University Shanghai Cancer Center, Shanghai, China.
Akif TurnaDepartment of Thoracic Surgery, Cerrahpasa Medical School, Istanbul University-Cerrahpasa, Istanbul, Turkey.
Yuan LiInstitute of Thoracic Oncology, Fudan University, Shanghai, China.
Yang ZhangDepartment of Thoracic Surgery and State Key Laboratory of Genetics and Development of Complex Phenotypes, Fudan University Shanghai Cancer Center, Shanghai, China.ORCID https://orcid.org/0000-0002-9081-0802
Haiquan ChenDepartment of Thoracic Surgery and State Key Laboratory of Genetics and Development of Complex Phenotypes, Fudan University Shanghai Cancer Center, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The prognostic implication of consolidation-to-tumor ratio (CTR) in patients with part-solid nodules (PSNs) remains ambiguous. The aim of this study is to explore the potential of CTR for refining prognostic stratification within the current clinical T1 classification. Methods: There were 1,340 N0M0 lung adenocarcinoma (LUAD) patients with PSNs (solid size ≤3 cm) enrolled. We constructed a novel risk stratification model based on both solid component size and CTR. The lung cancer-specific survival (LCSS) and recurrence-free survival (RFS) rates of the patients in the current and modified staging groups were evaluated. Results: At a median follow-up of 80.5 months, there were 89 recurrences and 40 lung cancer-associated deaths. The 5-year LCSS and RFS rates differed significantly in patients divided by CTR (0< CTR ≤0.5 Conclusions: CTR had a significant effect on the prognosis of PSNs, even when the solid component sizes were similar. An exploratory staging model incorporating CTR showed potential for improving risk stratification over the current T1 classification, but warrants external validation in future studies.

Indexed as

clinical T classificationconsolidation-to-tumor ratio (CTR)lung adenocarcinoma (LUAD)Part-solid nodule (PSN)

Identifiers

PMID41982683
PMCPMC13071782

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.